Biothera Pharmaceuticals is partnering with leaders in cancer immunotherapy to advance its unique technology and develop next generation immunotherapies.

Merck, a global health care leader for 125 years, is translating breakthrough science into innovative oncology medicines to help people with cancer worldwide.  

Biothera and Merck have multiple clinical trial collaborations to evaluate the safety and efficacy of Imprime PGG and KEYTRUDA® (Merck’s anti-PD-1 checkpoint inhibitor) in patients with advanced melanoma, metastatic triple negative breast cancer or head and neck squamous cell cancer.


For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. 

Biothera and Genentech, Inc., a member of the Roche Group, have a clinical trial collaboration to assess the safety and efficacy of Imprime PGG in combination with Genentech’s TECENTRIQ®, an anti-PD-L1 antibody, and AVASTIN®, an anti-VEGF antibody, to treat patients with metastatic colorectal cancer.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. 

Biothera and AstraZeneca have announced a clinical collaboration to evaluate Imprime PGG and IMFINZI® (durvalumab) in certain patients with head and neck cancer.  The Phase 2 neoadjuvant study will assess whether this therapeutic combination can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.

The Big Ten cancer centers are transforming cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities.

The Big Ten Cancer Research Consortium is conducting a Phase 1b/2 study in second line non-small cell lung cancer with KEYTRUDA and Imprime PGG, under separate collaboration agreements with Merck and Biothera. 

Dana-Farber Cancer Institute is committed to providing expert, compassionate care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases.

Dana-Farber Cancer Institute is conducting a Phase 2 clinical trial of Rituxan® (rituximab) and Imprime PGG in relapsed indolent B cell non-Hodgkin lymphoma.


Interested in partnering with Biothera?  We are actively exploring new partnership opportunities focused on enabling technologies and capabilities designed to bring life-saving therapies to patients. Please visit contact us.